🧬 New pancreatic cancer drug improves survival in phase 3 trial.
A phase 3 clinical trial has shown that the drug daraxonrasib can improve survival outcomes for pancreatic cancer patients. The treatment targets KRAS-mutated cancers, one of the most difficult forms to treat, marking a promising advance in precision oncology and cancer therapeutics.
👉 Read the full story: interestingengineering.com/health/darax...
Could targeted therapies like this change the future of pancreatic cancer treatment?
